Developing Next Generation Agents
for Psychedelic Therapy
Lophora is a clinical-stage biotech company developing novel, next generation
psychedelic agents to treat a multitude of psychiatric disorders
About us
Founded in 2018 Lophora has successfully finished initial characterization of its lead-candidate through funding granted by the BioInovation institute (Novo Nordisk Foundation) and will initiate first-in-human trials by 2024
News
Lophora Receives Additional Funding to Complete Pre-Clinical Development of LPH-5 – A Novel and Innovative Agent to Address Treatment-Resistant Depression
Founded by an initial investment of US$1.8M from the BioInnovation Institute (a Novo Nordisk Foundation Initiative), Lophora has received additional
- March 2, 2021